Mayne Pharma Appoints New President - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mayne Pharma Appoints New President



Mayne Pharma Group Limited has named Stefan Cross as president of Mayne Pharma USA. Cross is responsible for leading all of Mayne Pharma’s existing business operations and overseeing the expansion of Mayne Pharma’s pharmaceutical products division. In addition, Cross will manage the continued growth of contract pharmaceutical services as provided by Mayne Pharma’s subsidiary, Metrics.

Previously, Cross served as Mayne Pharma’s vice-president of business and corporate development, and played a role in the global commercialization of the company’s SUBACAP anti-fungal product. He has been involved inintegrating Metrics with Mayne Pharma, and in executing the company’s business strategy in Australia and the US. Cross headed marketing efforts in the Asia Pacific region for Hospira and led Hospira’s commercial operations in China, Hong Kong, and Taiwan. Prior to that, Cross worked for six years with Mayne Pharma Limited in Europe and Australia, and eight years with F.H. Faulding & Co. Limited.

Cross succeeds Phil Hodges, who founded Metrics and currently serves on the board of directors of Mayne Pharma Group Limited.

Source: Mayne Pharma Group Limited

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here